Effects of Short-term Growth Hormone in HIV-infected Patients

Inclusion Criteria: * previously diagnosed HIV infection * Stable antiretroviral regimen for at least 12 weeks prior to enrollment * Waist circumference \>/= 95cm and waist-to-hip ratio \>/= 0.94 for males or waist circumference \>/=94cm and WHR \>/= 0.88 for females, occurring in the context of treatment for HIV disease * Subjective evidence of at least one of the following changes, occurring during the treatment of HIV disease: increased abdominal girth, relative loss of fat in the extremities, or relative loss of fat in the face Exclusion Criteria: * Use of anti-diabetic agents, Megace, testosterone, or any steroid use within 6 months of the study * Use of GH or Growth hormone releasing factor within six months of starting the study * Change in lipid lowering or antihypertensive regimen within 3 months of screening * Fasting blood sugar \>126mg/dL, SGOT \> 2.5 times ULN, Hgb \< 12.0 g/dL, creatinine \> 1.4 mg/dL, FSH \> 20 IU/L in women, or CD4 count \< 200 * Carpal tunnel syndrome * Severe chronic illness or active malignancy or history of pituitary malignancy or history of colon cancer * For men, history of prostate cancer or evidence of prostate malignancy by PSA \> 5ng/mL * Prior history of hypopituitarism, head irradiation, or any other condition known to affect the GH axis * positive beta-HCG (women only) * Oral contraceptives, depo provera, or combined progesterone-estrogen injections, transdermal contraceptive patches, estrogen or progestin coated IUD's within 6 months of the study * weight \< 110 pounds